CNS prophylaxis for diffuse large B-cell lymphoma

12Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.
Get full text

Abstract

CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in the front-line treatment setting with the aim to reduce this subsequent risk. Clinical and biological features associated with elevated risk are increasingly well defined and are discussed in this Review. This Review summarises both the historical and current developments in this challenging field, provides a nuanced discussion regarding current reasons for and against standard prophylactic measures, outlines evidence for the timing of prophylactic measures when delivered, and reflects on possible future developments.

Cite

CITATION STYLE

APA

Eyre, T. A., Savage, K. J., Cheah, C. Y., El-Galaly, T. C., Lewis, K. L., McKay, P., … Ferreri, A. J. M. (2022, September 1). CNS prophylaxis for diffuse large B-cell lymphoma. The Lancet Oncology. Elsevier Ltd. https://doi.org/10.1016/S1470-2045(22)00371-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free